Printer Friendly

Shire wins US FDA approval for prescription medicine Mydayis to treat ADHD.

M2 PHARMA-June 21, 2017-Shire wins US FDA approval for prescription medicine Mydayis to treat ADHD

(C)2017 M2 COMMUNICATIONS

Biotechnology company Shire plc (LSE:SHP) (NASDAQ:SHPG) reported on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) for Mydayis for the treatment of patients 13 years and older with Attention Deficit Hyperactivity Disorder (ADHD).

The company said Mydayis (mixed salts of a single-entity amphetamine product) is a once-daily treatment comprised of three different types of drug-releasing beads for patients 13 years and older with ADHD. It is not for use in children 12 years and younger.

ADHD is a neurodevelopmental disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. The company expects to make Mydayis commercially available in the US in the third quarter of 2017.

US FDA approval of Mydayis is based on results from the company's 16 clinical studies in more than 1,600 subjects, including adolescents (aged 13 to 17 years) and adults with ADHD.

Under the company's pivotal, placebo-controlled clinical studies, Mydayis significantly improved symptoms of ADHD, as measured by the ADHD-RS-IV and the Permanent Product Measure of Performance (PERMP), in adults and adolescents. Improvement on the PERMP, an objective, validated, skill-adjusted math test that measures attention in ADHD patients, reached statistical significance beginning at two or four hours post-dose and lasting up to 16 hours post-dose.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 21, 2017
Words:246
Previous Article:Seattle Genetics suspends phase three acute myeloid leukaemia trial of vadastuximab talirine.
Next Article:Johnson & Johnson names Douglas Wallace, PhD winner of the 2017 Dr Paul Janssen Award.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters